BioCurate's Opportunity Assessment (BOA) applications now open: due 27 Aug 2021

from Andrew Bray, Senior BDM at CCS
T:+61 3 9903 0326; M: +61 (0)408 129 758
E: andrew.bray@monash.edu

BioCurate's Opportunity Assessment (BOA) applications are now open. All applications to be submitted via Monash Innovation. See detail and links to application form and information sheet in CCS deadline calendar and more below.

The internal deadline is COB Friday 27 August 2021.

Any questions prior to submission - please contact Bo Yun (bo.yun@monash.edu, Monash Innovation), Lynette Hogan (lynette.hogan@monash.edu, Monash Innovation) or Andrew Bray (andrew.bray@monash.edu, Snr BDM at CCS).

Final submissions to Monash Innovation at innovation@monash.edu and cc: Andrew, Bo and Lynette.

Please note:

In Scope - small molecule, antibody or other biological, peptides, cell therapy, gene therapy, drug/device/diagnostic combinations.

Out of Scope - diagnostics (unless companion), devices, veterinary medicines, vaccines.

A project must:

• Address an unmet clinical need
• Be clearly differentiated (preferably on efficacy) from other approaches on the market or in clinical development
• Have Commercial potential and clear potential for licensing
• Have a Clinical & Regulatory path that can be defined & executed
• Target must have verified link to human disease
• Be supported by robust, reproducible scientific data & validated reagents & assays
• Have no IP “showstoppers”
• Existing IP not necessary, but must have clear IP potential
• No known freedom-to-operate issues